Tag Archives: TNF Inhibitors

June, 2017

16 June
Lilly’s Taltz Significantly Improves Disease Signs and Symptoms in Psoriatic Arthritis Patients with Inadequate Response or Intolerance to TNF Inhibitors

altz INDIANAPOLIS, June 15, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that patients with active psoriatic arthritis (PsA) who had inadequate response to one or two TNF inhibitors or were intolerant of TNF inhibitors treated with Taltz® (ixekizumab) achieved significant improvement in signs and symptoms of …
Share

20 November
EU Endorses Biogen and Samsung Bioepis’ Biosimilar Version of Enbrel

ZUG, Switzerland–(BUSINESS WIRE)–Biogen (NASDAQ:BIIB) today announced further progress as part of its commitment to biosimilars. Samsung Bioepis, the joint venture between Samsung Biologics and Biogen, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the marketing authorization …
Share

19 October
Janssen Presents Positive Results from its Phase III Study in Crohn’s Disease

HONOLULU, Oct. 19, 2015 /PRNewswire/ — Phase 3 data presented for the first time showed treatment with STELARA®(ustekinumab) induced clinical response and clinical remission in patients with moderate to severe Crohn’s disease who had previously failed conventional therapy, the majority of whom were naive to treatment with anti-tumor necrosis factor …
Share